Do we really need another paper on prognosis? The topic has been explored exhaustively. We have seen studies identifying the ability of myocardial perfusion imaging (MPI) to stratify prognosis with planar imaging and SPECT, thallium, sestamibi, tetrofosmin, dual isotope, and rubidium. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] We have heard about prognosis using treadmill exercise and pharmacologic stress using dipyridamole, adenosine, and dobutamine. 5, 10, [12] [13] [14] [15] We have read studies looking at men, women, metabolic syndrome, obesity, diabetics, and patients with endstage renal disease. 5, [16] [17] [18] [19] [20] The literature is peppered with studies looking at low and intermediate Duke treadmill scores, patients with LBBB, left ventricular hypertrophy, and normal EKGs. 12, [21] [22] [23] There are papers looking at patients with suspected coronary disease, catheterization documented coronary disease, stable angina, and post infarction patients. 10, 13, 24, 25 When it seems that the list is complete, when every conceivable subgroup has been identified and studied, Doukky et al 26 have managed to identify yet another group: MPI in an outpatient primary care setting. As a group, this referral population would be expected to have less acuity and presumably a better prognosis, but as this group is more reflective of the general population it certainly merits careful scrutiny.
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They identified a consecutive series of 1,546 patients of whom greater than 1400 met entry criteria; a mean follow-up of 27 months was obtained in 99%. The majority of the scans were normal, only 12.5% were deemed abnormal due to perfusion defects, decreased function or both. Not surprisingly, the overall cardiac event rates were both hard events (mortality and myocardial infarction) and revascularization were low. Cox analysis once again showed that an abnormal MPI was a strong predictor of cardiac events while the overall event rates in patients with normal scans was quite low (0.54% death or MI) somewhat lower than the approximately 1% rate reported in cardiologist-based practices. The summed stress score, as in previous studies, showed a stepwise influence on prognosis.
The study was performed using only a single blinded reader using semi-quantitative analysis with commercially available software. It should be noted that the authors used a SSS of C1 as abnormal, a deviation from most of the published literature. This is unlikely to effect the conclusions as the most important finding is the correlation between SSS and outcome and not where the line between normal and abnormal is drawn.
This study raises important questions about appropriateness. This includes not just whether the indication for the test was appropriate but also the appropriate follow-up of abnormal tests and the appropriateness of the appropriate use criteria themselves. The authors report that nearly half the studies ordered were classified as inappropriate under the current AUC criteria. It is noted that AUC criteria were not as widely recognized during the time the study was conducted; it would not be surprising if the clinical practice of the ordering physicians has changed since then reflecting better recognition and adoption of these criteria. It is also likely that primary care physicians will be slower to incorporate the AUC guidelines than cardiologists.
The appropriateness of evaluation of patients with abnormal scans is perhaps a greater concern. Less than half of the patients with significantly abnormal MPI underwent catheterization and only one-third were revascularized. The authors suggest that this reflects inappropriate patient selection but could also reflect poor understanding of the clinical implications of a significantly abnormal study in a primary care setting. Presumably, once a patient makes it to the catheterization laboratory, clinical decisions will be strongly influenced by cardiologists. One is much less certain about the other half that were not catheterized and whether this high risk group received optimal care.
Finally, this study raises questions about the appropriate use criteria themselves. It is not surprising that patients meeting AUC criteria had a higher percentage of abnormal MPI (13.3% vs 6.9%), which reflects the AUC's criteria for identifying higher risk patients. The concern is the relatively high rate of positive scans in the inappropriate group. Of course, the simple finding of a positive scan does not invalidate the AUC; outcomes data would be needed to definitively answer this question. But the positive scan rate of nearly 7% in a presumably low risk group should give us pause. We are all witnessing the bureaucratization of clinical decision making borne of desire to reduce costs and mistrust of physician motivations when ordering tests. Challenging clinical judgement, without clear understanding of its implications on patient outcome can have dire consequences; this study only adds to these concerns. Clearly, further study is needed. This paper joins the now very long list of studies that have consistently shown the ability of MPI to assess prognosis in virtually every subgroup studied and reinforces the superiority of physiology over anatomy when it comes to evaluating patients with coronary disease. The preeminence of physiology as the arbitrator of the optimal treatment of a patient with stable angina pectoris has lately gained overwhelming support from a totally different venue. Investigators using fractional flow reserve in the FAME I-II and DEFER trials convincingly demonstrated that the physiologic effect of a coronary stenosis is the most important factor in identifying patients most likely to benefit from revascularization. [27] [28] [29] Prognosis is the past, present, and future of nuclear cardiology. So, yes, another paper on prognosis is welcome.
